WO2010043866A3 - Inhibiteurs d’histone lysine déméthylase - Google Patents

Inhibiteurs d’histone lysine déméthylase Download PDF

Info

Publication number
WO2010043866A3
WO2010043866A3 PCT/GB2009/002465 GB2009002465W WO2010043866A3 WO 2010043866 A3 WO2010043866 A3 WO 2010043866A3 GB 2009002465 W GB2009002465 W GB 2009002465W WO 2010043866 A3 WO2010043866 A3 WO 2010043866A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
derivative
formula
histone lysine
activation
Prior art date
Application number
PCT/GB2009/002465
Other languages
English (en)
Other versions
WO2010043866A2 (fr
Inventor
Christopher Joseph Schofield
Michael Mcdonough
Nathan Rose
Armin Thalhammer
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Publication of WO2010043866A2 publication Critical patent/WO2010043866A2/fr
Publication of WO2010043866A3 publication Critical patent/WO2010043866A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Cette invention concerne un composé qui est un dérivé de iV-oxalylglycine de formule (I) : un dérivé d’acide hydroxamique de formule (II) : ou un dérivé hétéroaryle de formule (III) : n, Z1, Z2, Y1, Y2, A, p, X1, X2, m, R4, B, R5, R6, R7, R8, R9, X3, R10, R11 et R12 étant tels que définis dans la description, ou un de leurs sels pharmaceutiquement acceptables. Ces composés sont des inhibiteurs de la sous-famille des JMJD2 humains à 2-oxoglutarate des histone déméthylases, en particulier les JMJD2E. Ces inhibiteurs sont utilisés pour changer l’état épigénétique des cellules entraînant l’inhibition/l’activation de la recomposition de la chromatine, l’activation/la désactivation de multiples gènes, et dans le traitement du cancer et d’autres maladies caractérisées par une prolifération cellulaire indésirable et des troubles psychiatriques y compris la dépression.
PCT/GB2009/002465 2008-10-15 2009-10-15 Inhibiteurs d’histone lysine déméthylase WO2010043866A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0818907.8 2008-10-15
GBGB0818907.8A GB0818907D0 (en) 2008-10-15 2008-10-15 Histone lysine demethylase inhibitors

Publications (2)

Publication Number Publication Date
WO2010043866A2 WO2010043866A2 (fr) 2010-04-22
WO2010043866A3 true WO2010043866A3 (fr) 2010-10-07

Family

ID=40084077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002465 WO2010043866A2 (fr) 2008-10-15 2009-10-15 Inhibiteurs d’histone lysine déméthylase

Country Status (2)

Country Link
GB (1) GB0818907D0 (fr)
WO (1) WO2010043866A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2860178B1 (fr) * 2008-10-31 2021-01-13 Merck Sharp & Dohme Corp. Antagonistes du récepteur P2X3 pour le traitement de la douleur
GB0918862D0 (en) * 2009-10-27 2009-12-09 Glaxo Group Ltd Method of treatment
WO2012007008A1 (fr) * 2010-07-15 2012-01-19 Epitherapeutics Aps Inhibiteurs de hdme
WO2012012627A1 (fr) * 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Méthode destinée à prévenir ou à traiter une infection virale
GB201112607D0 (en) * 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
TWI429637B (zh) * 2011-04-01 2014-03-11 Nat Univ Tsing Hua 衍生自４，４’－二酸－２，２’－雙吡啶之三牙配位子、金屬錯合物及其應用
WO2012150042A1 (fr) 2011-05-04 2012-11-08 Cellzome Ag Composés et procédés pour identifier des molécules ayant une interaction avec les histones déméthylases et pour purifier des protéines d'histone déméthylase
EP2592154A1 (fr) 2011-11-09 2013-05-15 Cellzome Ag Produits d'immobilisation et procédés d'identification de molécules d'interaction de déméthylase d'histone et de purification des protéines de déméthylase d'histone
WO2013143597A1 (fr) 2012-03-29 2013-10-03 Glaxo Group Limited Inhibiteurs d'enzymes de déméthylase
ES2834959T3 (es) 2012-12-06 2021-06-21 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
CA2903081A1 (fr) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Inhibiteurs d'histone demethylase
EP3039009B1 (fr) * 2013-08-30 2019-05-01 The University of British Columbia Composés inhibiteurs à sélectivité mao-b, compositions pharmaceutiques les contenant et utilisations correspondantes
CN105566145A (zh) * 2014-11-03 2016-05-11 广州德汇行医药科技有限公司 氨基酸衍生物及其应用
EP3313420B1 (fr) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Procédés et compositions se rapportant à l'expansion, l'enrichissement et la conservation de cellules souches hématopoïétiques
EP4049665A1 (fr) 2016-03-15 2022-08-31 Children's Medical Center Corporation Procédés et compositions associées à l'expansion de cellules souches hématopoïétiques
WO2017207813A1 (fr) 2016-06-03 2017-12-07 Oryzon Genomics, S.A. Acides hétéroaryl-carboxyliques utilisés en tant qu'inhibiteurs de l'histone déméthylase
WO2018148206A1 (fr) * 2017-02-10 2018-08-16 Temple Otorongo Llc Traitement du diabète et d'états métaboliques associés au moyen de modulateurs épigénétiques
WO2018149986A1 (fr) * 2017-02-16 2018-08-23 Oryzon Genomics, S.A. Dérivés de 2-(bicyclo-hétéroaryl)-isonicotinique en tant qu'inhibiteurs d'histone déméthylase
WO2018219478A1 (fr) 2017-06-02 2018-12-06 Oryzon Genomics, S.A. Hétéroaryl-carboxamides comme inhibiteurs de l'histone déméthylase
CN107540574B (zh) * 2017-09-19 2021-06-11 成都西岭源药业有限公司 R-联苯丙氨醇的制备方法
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN109438339A (zh) * 2018-12-22 2019-03-08 山东大学 Rbp2酶抑制剂小分子化合物wxsa-072a及其制备方法与抗胃癌应用
CN109456262A (zh) * 2018-12-22 2019-03-12 山东大学 基于抑制组蛋白去甲基化酶化合物及其制备方法与抗胃癌应用
CN114409557B (zh) * 2022-01-19 2022-08-30 中南民族大学 一种具有神经保护活性的炭角酸及其制备方法和应用

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214639A2 (fr) * 1985-09-10 1987-03-18 G.D. Searle & Co. Inhibiteurs de collagénase dérivés d'acides hydroxamique
WO1988008422A1 (fr) * 1987-04-22 1988-11-03 Schering Aktiengesellschaft Complexants cyliques substitues, complexes et sels de complexes, leur procede de production et substances pharmaceutiques les contenant
EP0489579A1 (fr) * 1990-12-03 1992-06-10 Celltech Therapeutics Limited Dérivés peptidyliques
WO1995012603A1 (fr) * 1993-11-04 1995-05-11 Syntex (U.S.A.) Inc. Inhibiteurs de metalloproteases matricielles
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
WO1997043249A1 (fr) * 1996-05-10 1997-11-20 Smithkline Beecham Plc INHIBITEURS DE LA PRODUCTION DE s-CD23 ET DE LA SECRETION DE TNF
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
WO1998014424A1 (fr) * 1996-10-02 1998-04-09 Novartis Ag Derives d'acide hydroxamique
EP0848957A1 (fr) * 1995-09-08 1998-06-24 Kanebo Ltd. INHIBITEUR DE SOLUBILISATION DE LIGAND Fas
WO1999044989A1 (fr) * 1998-03-03 1999-09-10 Leo Pharmaceutical Products Ltd. A/S Inhibiteurs de metalloprotease matricielle
WO2002000593A2 (fr) * 2000-06-23 2002-01-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composes utiles pour la preparation de medicaments exerçant une activite d'inhibition de la phosphodiesterase iv
WO2005027856A2 (fr) * 2003-03-17 2005-03-31 Cengent Therapeutics Inhibiteurs du facteur letal du charbon
US20070208082A1 (en) * 2005-08-10 2007-09-06 John Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
WO2009113320A1 (fr) * 2008-03-13 2009-09-17 株式会社ヤクルト本社 Inhibiteur de mmp

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214639A2 (fr) * 1985-09-10 1987-03-18 G.D. Searle & Co. Inhibiteurs de collagénase dérivés d'acides hydroxamique
WO1988008422A1 (fr) * 1987-04-22 1988-11-03 Schering Aktiengesellschaft Complexants cyliques substitues, complexes et sels de complexes, leur procede de production et substances pharmaceutiques les contenant
EP0489579A1 (fr) * 1990-12-03 1992-06-10 Celltech Therapeutics Limited Dérivés peptidyliques
WO1995012603A1 (fr) * 1993-11-04 1995-05-11 Syntex (U.S.A.) Inc. Inhibiteurs de metalloproteases matricielles
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
EP0848957A1 (fr) * 1995-09-08 1998-06-24 Kanebo Ltd. INHIBITEUR DE SOLUBILISATION DE LIGAND Fas
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
WO1997043249A1 (fr) * 1996-05-10 1997-11-20 Smithkline Beecham Plc INHIBITEURS DE LA PRODUCTION DE s-CD23 ET DE LA SECRETION DE TNF
WO1998014424A1 (fr) * 1996-10-02 1998-04-09 Novartis Ag Derives d'acide hydroxamique
WO1999044989A1 (fr) * 1998-03-03 1999-09-10 Leo Pharmaceutical Products Ltd. A/S Inhibiteurs de metalloprotease matricielle
WO2002000593A2 (fr) * 2000-06-23 2002-01-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composes utiles pour la preparation de medicaments exerçant une activite d'inhibition de la phosphodiesterase iv
WO2005027856A2 (fr) * 2003-03-17 2005-03-31 Cengent Therapeutics Inhibiteurs du facteur letal du charbon
US20070208082A1 (en) * 2005-08-10 2007-09-06 John Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
WO2009113320A1 (fr) * 2008-03-13 2009-09-17 株式会社ヤクルト本社 Inhibiteur de mmp

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ANNA A. KARKHANINA ET AL: "Direct Analysis of Enzyme-Catalyzed DNA Demethylation", ANAL. CHEM., vol. 81, no. 14, 15 July 2009 (2009-07-15), pages 5871 - 5875, XP002573981 *
BAILEY S ET AL: "Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 8, no. 1-6, 6 January 1998 (1998-01-06), pages 23 - 28, XP004136616, ISSN: 0960-894X *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 September 2009 (2009-09-17), NISHIYAMA, HIROYUKI ET AL: "Preparation of N-[3-(hydroxycarbamoyl)propanoyl]-L- amino acid amide derivatives as matrix metalloproteinase (MMP) inhibitors", XP002574033, retrieved from STN Database accession no. 2009:1139100 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002, HOU, TING-JUN ET AL: "Binding free energy calculations for MMP2 -hydroxamate complexes", XP002574032, retrieved from STN Database accession no. 2002:161702 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 31 March 1997 (1997-03-31), HORIO, YOSHIHIRO ET AL: "Preparation of N-[N-(phosphonomethyl)aminocarbonyl]-.beta.-arylalanine derivatives as specific inhibitors of metallopeptidase, angiotensin converting enzyme, and endothelin-converting enzyme, and enkephalinase", XP002573978, retrieved from STN Database accession no. 1997:377271 *
DECICCO C P ET AL: "Amide surrogates of matrix metalloproteinase inhibitors: urea and sulfonamide mimics", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 7, no. 18, 23 September 1997 (1997-09-23), pages 2331 - 2336, XP004136439, ISSN: 0960-894X *
DI STEFANO A ET AL: "Synthesis and preliminary evaluation of L-dopa/benserazide conjugates as dual acting codrugs", LETTERS IN DRUG DESIGN AND DISCOVERY, BENTHAM SCIENCE PUBLISHERS, US, vol. 3, no. 10, 1 December 2006 (2006-12-01), pages 747 - 752, XP008100266, ISSN: 1570-1808 *
DONNECKE ET AL: "From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 12, 15 June 2007 (2007-06-15), pages 3322 - 3329, XP022097777, ISSN: 0960-894X *
FRAY M J ET AL: "Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (Stromelysin-1)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 11, no. 4, 26 February 2001 (2001-02-26), pages 571 - 574, XP004230062, ISSN: 0960-894X *
HUAXUE XUEBAO , 60(2), 221-227 CODEN: HHHPA4; ISSN: 0567-7351, 2002 *
JACOBSON I C ET AL: "Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 8, no. 7, 7 April 1998 (1998-04-07), pages 837 - 842, XP004136975, ISSN: 0960-894X *
NATHAN R. ROSE ET AL: "Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demthylases", J. MED. CHEM., vol. 51, 23 October 2008 (2008-10-23), pages 7053 - 7056, XP002573979 *
PORTER J R ET AL: "POTENT AND SELECTIVE INHIBITORS OF GELATINASE-A. 1. HYDROXAMIC ACID DERIVATIVES", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 4, no. 23, 1 January 1994 (1994-01-01), pages 2741 - 2746, XP000671434, ISSN: 0960-894X *
TUSSETSCHLAEGER STEFAN ET AL: "Synthesis of 5-methoxy-4-benzyloxazoles from tyrosine and m-tyrosine under Bischler-Napieralski conditions", ZEITSCHRIFT FUR NATURFORSCHUNG, TEIL B:ANORGANISCHE CHEMIE, ORGANISCHE CHEMIE, VERLAG DER ZEITSCHRIFT FUR NATURFORSCHUNG. TUBINGEN, DE, vol. 61, no. 4, 1 January 2006 (2006-01-01), pages 420 - 426, XP009087383, ISSN: 0932-0776 *
YAMAMOTO M ET AL: "INHIBITION OF MEMBRANE-TYPE 1 MATRIX METALLOPROTEINASE BY HYDROXAMATE INHIBITORS: AN EXAMINATION OF THE SUBSITE POCKET", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 41, no. 8, 1 January 1998 (1998-01-01), pages 1209 - 1217, XP000867897, ISSN: 0022-2623 *
YAMAMOTO M ET AL: "Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-.alpha. processing", DRUG DESIGN AND DISCOVERY, HARWOOD ACADEMIC PUBLISHERS GMBH, XX, vol. 16, 1 January 1999 (1999-01-01), pages 119 - 130, XP009130971, ISSN: 1055-9612 *

Also Published As

Publication number Publication date
WO2010043866A2 (fr) 2010-04-22
GB0818907D0 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
WO2010043866A3 (fr) Inhibiteurs d’histone lysine déméthylase
WO2006061638A3 (fr) Derives heterocycliques utilises comme inhibiteurs d'histone desacetylase (hdac)
WO2010144378A3 (fr) Composés inhibiteurs de hdac de cycloalkylcarbamate-benzamide-aniline
WO2010009139A3 (fr) Composés inhibiteurs de pyrimidine imidazolyle
WO2008055068A8 (fr) Inhibiteurs de l'histone désacétylase
EP2331530B8 (fr) Composés multicycliques fusionnés en tant qu inhibiteurs des protéines kinases
WO2007011626A3 (fr) Inhibiteurs de l'histone deacetylase
WO2007084390A3 (fr) Inhibiteurs des histone desacetylases
WO2009053808A3 (fr) Inhibiteurs d'histone désacétylase
WO2007029035A3 (fr) Derives de trifluoroethanone a substitution thiophene et thiazole utilises comme inhibiteurs de l'histone desacetylase (hdac)
WO2012030685A3 (fr) Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2010046445A3 (fr) Dérivées d’urée de nortropanes substitués, médicaments contenant de tels composés et leur utilisation
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
AU2010302572A8 (en) New histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers
HK1128286A1 (en) Heterocyclylalkyl derivatives as inhibitors of histone deacetylase
EP2573069A3 (fr) Inhibiteurs d'histone désacétylase et leurs promédicaments
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
WO2008057775A3 (fr) Composés d'amide hétérocyclique utiles comme inhibiteurs de kinase
WO2006023515A3 (fr) Nouveaux inhibiteurs thiazole de la fructose 1,6-bisphosphatase
EA200401199A1 (ru) Ингибиторы гистондеацетилазы
WO2006066133A3 (fr) Inhibiteurs d'histone desacetylase
WO2006122319A3 (fr) Inhibiteurs d'histone deacetylase
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
WO2009077874A3 (fr) Composition pharmaceutique pour traiter le cancer de l'œsophage
WO2007010085A3 (fr) Nouveaux composes pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09736636

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09736636

Country of ref document: EP

Kind code of ref document: A2